Results
1 -
6 of
6Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib, Cancer Chemotherapy and Pharmacology Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer, Cancer Chemotherapy and Pharmacology Famitinib, Reactions Weekly Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial, Chinese Journal of Cancer